11/14
08:15 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
11/13
08:00 am
mltx
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
Medium
Report
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
11/8
02:32 pm
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
11/7
07:00 am
mltx
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
Low
Report
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
11/6
06:33 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) was upgraded by analysts at Wedbush to a "strong-buy" rating.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) was upgraded by analysts at Wedbush to a "strong-buy" rating.
11/5
08:17 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $73.00 price target on the stock, down previously from $92.00.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $73.00 price target on the stock, down previously from $92.00.
10/15
08:47 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
10/13
04:26 am
mltx
MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold [Seeking Alpha]
Low
Report
MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold [Seeking Alpha]
9/23
08:53 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/16
05:48 pm
mltx
Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases [Seeking Alpha]
Low
Report
Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases [Seeking Alpha]
9/12
08:11 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $62.00 price target on the stock.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $62.00 price target on the stock.
9/12
08:11 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
9/9
02:14 pm
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/9
07:00 am
mltx
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
Low
Report
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
8/27
08:33 pm
mltx
MoonLake Immunotherapeutics (MLTX): One of Oppenheimer's Top Stock Picks For the Next 12 Months [Yahoo! Finance]
Low
Report
MoonLake Immunotherapeutics (MLTX): One of Oppenheimer's Top Stock Picks For the Next 12 Months [Yahoo! Finance]
8/26
08:03 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.